Newsroom
Tuesday, 30 October 2018
REKOVELLE®, the first recombinant follicle stimulating hormone derived from a human cell line, is now available for Canadian women undergoing IVF and other assisted reproductive technologies.
Toronto, Ontario – 29 October 2018 – Ferring Pharmaceuticals announced that REKOVELLE® (follitropin delta injection), the first recombinant FSH for controlled ovarian stimulation derived from a human cell line, is now available in Canada for women undergoing assisted reproductive technologies such as in vitro fertilization (IVF).